Fndc3c1 Inhibitors
The chemical class known as FNDC3C1 Inhibitors comprises a range of compounds that can indirectly modulate the function or influence of FNDC3C1 within cellular contexts. These inhibitors target various signaling molecules and pathways that may intersect with the functional landscape of FNDC3C1. For example, PF-573228 and CCG-1423 inhibit proteins such as FAK and RhoA, respectively, which play critical roles in cell adhesion and actin cytoskeleton organization. Since FNDC3C1 is a protein that may be implicated in similar cellular processes, the modulation of these pathways can alter the activity or the context in which FNDC3C1 operates.
Similarly, inhibitors like LY294002, U0126, and Wortmannin target key kinases within the PI3K/AKT and MAPK/ERK pathways, which are integral to a multitude of cellular functions, including those that FNDC3C1 could affect. By manipulating these pathways, the inhibitors can indirectly influence the functional outcomes associated with FNDC3C1. Compounds such as Y-27632, SP600125, and SB203580, which target ROCK, JNK, and p38 MAPK, respectively, also contribute to this indirect modulation by influencing the cytoskeletal dynamics and stress response signaling in which FNDC3C1 may play a part. Furthermore, Gö6976, Blebbistatin, and ML7 can affect processes related to cellular signaling and motility by inhibiting PKC, myosin II ATPase, and myosin light chain kinase, respectively, potentially altering the functional environment of FNDC3C1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CCG-1423 | 285986-88-1 | sc-205241 sc-205241A | 1 mg 5 mg | $30.00 $90.00 | 8 | |
An inhibitor of RhoA signaling which is involved in the regulation of the actin cytoskeleton, potentially affecting FNDC3C1's interaction with the cytoskeleton. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that can affect cytoskeletal dynamics and cell adhesion, potentially impacting processes FNDC3C1 is involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that can alter various cellular signaling pathways, potentially affecting FNDC3C1's role within these pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor that can modulate the MAPK/ERK pathway, potentially influencing FNDC3C1-mediated cellular functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that can affect cell signaling related to stress responses, potentially influencing FNDC3C1 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor which can modulate inflammatory responses and cytoskeletal changes, potentially impacting FNDC3C1's role in these processes. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
A classic PKC inhibitor that can affect signal transduction pathways, potentially altering FNDC3C1's function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
An inhibitor of PI3K, affecting various signaling pathways which can modulate FNDC3C1's role in cellular processes. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
An inhibitor of myosin II ATPase activity, affecting muscle contraction and cell motility, potentially impacting FNDC3C1's function. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
An inhibitor of myosin light chain kinase which can affect cell motility and structure, potentially influencing FNDC3C1's cellular role. | ||||||